Relmada Therapeutics, Inc. RLMD General and administrative costs
General and administrative costs at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s general and administrative costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s general and administrative costs?
- Relmada Therapeutics, Inc. (RLMD) reported general and administrative costs of $11.37M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s general and administrative costs changed year-over-year?
- Relmada Therapeutics, Inc.'s general and administrative costs increased by 81.5% year-over-year, from $6.27M to $11.37M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s general and administrative costs?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s general and administrative costs has grown at a -2.1% compound annual growth rate (CAGR), from $35.08M to $32.22M.
- What does general and administrative costs mean?
- Includes costs associated with the management, legal, human resources, and corporate overhead functions of the organization. These expenses are essential for maintaining corporate operations but do not directly contribute to the research or production of specific drug candidates.